Showing results (131-140 of 312) with videos related to
Sort By:
Pageof 32
Academic Radiology|September 25, 2012
Hyperpolarized (3)He magnetic resonance imaging: comparison with four-dimensional x-ray computed tomography imaging in lung cancerLindsay Mathew, Andrew Wheatley, Richard Castillo, et al.The Canadian Journal of Urology|December 26, 2006
Controversies in prostate cancer staging implementation at a tertiary cancer centerTracy Sexton, George Rodrigues, Ed Brecevic, et al.Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 19, 2012
Pre-treatment risk stratification of prostate cancer patients: A critical reviewGeorge Rodrigues, Padraig Warde, Tom Pickles, et al.Radiation Oncology (London, England)|March 23, 2012
A phase II multi-institutional study assessing simultaneous in-field boost helical tomotherapy for 1-3 brain metastasesGeorge Rodrigues, Slav Yartsev, Keng Yeow Tay, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2010
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimensJoaquim Bellmunt, Toni K Choueiri, Ronan Fougeray, et al.Clinical Chemistry|March 28, 2009
New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAsPieter H Anborgh, Sylvia M Wilson, Alan B Tuck, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2017
Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical OpinionKatherine S Virgo, Ethan Basch, D Andrew Loblaw, et al.Investigational New Drugs|March 2, 2010
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II ConsortiumSrikala S Sridhar, Eric Winquist, Andrea Eisen, et al.The Oncologist|November 7, 2015
Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate CancerUrban Emmenegger, Christopher M Booth, Scott Berry, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06cFred Saad, Sebastien Hotte, Scott North, et al.Pageof 32